Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PET Scan with PF-03654746 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | This arm will have no active treatment. |
| Cohort 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Positron Emission tomography | OTHER | Positron Emission tomography scans. Part 1of the study : 4 subjects will receive 2 scans a day for 1 day with PET ligand administered in tracer quantities. |
| PET Scan with PF-03654746 | DRUG | If none of the data from Cohort 2 is informative, then: 2) an additional 3 subjects will receive 2 Scans on Day 1 and 1 scan on Day 2 following 3 different doses of PF-03654746. Doses will be determined based upon the outcome of the first intervention. |
Inclusion Criteria: * Healthy male subjects between the ages of 18 and 55 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical l...
PET Scan with PF-03654746 is a Phase 1 positron emission tomography imaging approach that uses the small molecule PF-03654746 as a radiotracer to visualize its distribution in the body. It was studied in healthy male volunteers in the United States. The study is completed and no indication has been disclosed.
PET Scan with PF-03654746 is being developed by Pfizer, Inc., which trades under the ticker PFE. Pfizer sponsored the Phase 1 healthy volunteer PET imaging study of this small molecule tracer.
PET Scan with PF-03654746 is in Phase 1 development. The only listed trial is a completed Phase 1 positron emission tomography study in healthy volunteers. It is investigational and has not been approved for any use.
PET Scan with PF-03654746 has been studied in one clinical trial, NCT00730990, titled A Phase I, Healthy Volunteer Positron Emission Tomography Study. It was a completed Phase 1 trial with 10 enrolled participants, conducted in the United States.
PET Scan with PF-03654746 is used as a positron emission tomography imaging agent in research settings. The Phase 1 trial evaluated it in healthy male volunteers aged 18 years and older. No therapeutic indication has been disclosed for this imaging approach.